Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Analysts

Agenus Inc. (NASDAQ:AGEN) has received a consensus rating of “Hold” from the six research firms that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $10.00.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a report on Wednesday, January 22nd.

Agenus Price Performance

Shares of AGEN stock opened at $3.51 on Tuesday. The stock’s fifty day simple moving average is $3.25 and its 200 day simple moving average is $4.32. The firm has a market cap of $82.34 million, a price-to-earnings ratio of -0.31 and a beta of 1.30. Agenus has a one year low of $2.50 and a one year high of $19.69.

Hedge Funds Weigh In On Agenus

A number of large investors have recently made changes to their positions in AGEN. Apollon Wealth Management LLC acquired a new stake in shares of Agenus in the 4th quarter valued at $55,000. Barclays PLC lifted its holdings in Agenus by 295.3% during the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock worth $152,000 after buying an additional 20,777 shares during the period. Geode Capital Management LLC raised its position in shares of Agenus by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after acquiring an additional 32,016 shares in the last quarter. EP Wealth Advisors LLC bought a new position in shares of Agenus in the 3rd quarter worth about $55,000. Finally, State Street Corp raised its stake in Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after buying an additional 9,731 shares during the period. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.